Chemomab Therapeutics Analyst Ratings
Chemomab Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/06/2023 | 681.25% | Roth MKM | → $7 | Initiates Coverage On | → Buy |
| 06/07/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 04/18/2023 | 681.25% | Oppenheimer | $12 → $7 | Maintains | Outperform |
| 03/10/2022 | 2132.14% | Oppenheimer | $30 → $20 | Maintains | Outperform |
| 12/07/2021 | 3248.21% | Aegis Capital | → $30 | Initiates Coverage On | → Buy |
| 05/26/2021 | 4922.32% | Cantor Fitzgerald | → $45 | Initiates Coverage On | → Overweight |
| 05/07/2021 | 4587.5% | Oppenheimer | → $42 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/06/2023 | 681.25% | 羅斯MKM | →$7 | 開始承保 | →購買 |
| 06/07/2023 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 04/18/2023 | 681.25% | 奧本海默 | $12→$7 | 維護 | 跑贏大盤 |
| 03/10/2022 | 2132.14% | 奧本海默 | $30→$20 | 維護 | 跑贏大盤 |
| 12/07/2021 | 3248.21% | 宙斯盾資本 | →$30 | 開始承保 | →購買 |
| 2021/05/26 | 4922.32% | 康託·菲茨傑拉德 | →$45 | 開始承保 | →超重 |
| 05/07/2021 | 4587.5% | 奧本海默 | →$42 | 開始承保 | →跑贏大盤 |
What is the target price for Chemomab Therapeutics (CMMB)?
Chemomab Treeutics(CMMB)的目標價格是多少？
The latest price target for Chemomab Therapeutics (NASDAQ: CMMB) was reported by Roth MKM on October 6, 2023. The analyst firm set a price target for $7.00 expecting CMMB to rise to within 12 months (a possible 681.25% upside). 3 analyst firms have reported ratings in the last year.
Roth MKM於2023年10月6日報道了Chemomab治療公司(納斯達克代碼：CMMB)的最新目標價。這家分析公司將目標價定為7美元，預計CMMB將在12個月內上漲(可能上漲681.25%)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Chemomab Therapeutics (CMMB)?
化學單抗治療公司(CMMB)的最新分析師評級是什麼？
The latest analyst rating for Chemomab Therapeutics (NASDAQ: CMMB) was provided by Roth MKM, and Chemomab Therapeutics initiated their buy rating.
Roth MKM提供了對Chemomab Treeutics(納斯達克代碼：CMMB)的最新分析師評級，Chemomab Treeutics啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for Chemomab Therapeutics (CMMB)?
化學單抗治療(CMMB)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemomab Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemomab Therapeutics was filed on October 6, 2023 so you should expect the next rating to be made available sometime around October 6, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Chemomab治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Chemomab治療公司的上一次評級是在2023年10月6日提交的，所以你應該預計下一次評級將在2024年10月6日左右的某個時候提供。
Is the Analyst Rating Chemomab Therapeutics (CMMB) correct?
分析師對Chemomab Treeutics(CMMB)的評級正確嗎？
While ratings are subjective and will change, the latest Chemomab Therapeutics (CMMB) rating was a initiated with a price target of $0.00 to $7.00. The current price Chemomab Therapeutics (CMMB) is trading at is $0.90, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Chemomab治療(CMMB)評級是以0.00美元至7.00美元的目標價啟動的。Chemomab Treateutics(CMMB)目前的交易價格為0.9美元，在分析師的預測範圍內。